These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3289524)

  • 21. Acute administration of alprazolam has no effect on plasma homovanillic acid concentration in normal subjects.
    Zemishlany Z; Davidson M; Jaff S; McQueeney R
    Schizophr Res; 1991; 5(1):81-3. PubMed ID: 1677266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined alprazolam and neuroleptic drug in treating schizophrenia.
    Bacher NM; Lewis HA; Field PB
    Am J Psychiatry; 1986 Oct; 143(10):1311-3. PubMed ID: 2876649
    [No Abstract]   [Full Text] [Related]  

  • 23. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.
    Pickar D; Owen RR; Litman RE; Konicki E; Gutierrez R; Rapaport MH
    Arch Gen Psychiatry; 1992 May; 49(5):345-53. PubMed ID: 1375019
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M; Kahn RS; Powchik P; Warne P; Losonczy MF; Kaminsky R; Apter S; Jaff S; Davis KL
    Arch Gen Psychiatry; 1991 Jan; 48(1):73-6. PubMed ID: 1670618
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postpsychotic depression and negative symptoms: an investigation of syndromal overlap.
    Siris SG; Adan F; Cohen M; Mandeli J; Aronson A; Casey E
    Am J Psychiatry; 1988 Dec; 145(12):1532-7. PubMed ID: 3057924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.
    Odejide OA; Aderounmu AF
    J Clin Psychiatry; 1982 May; 43(5):195-6. PubMed ID: 7076630
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia.
    Kane JM; Rifkin A; Quitkin F; Nayak D; Ramos-Lorenzi J
    Arch Gen Psychiatry; 1982 Jan; 39(1):70-3. PubMed ID: 6275811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, EEG mapping and psychometric studies in negative schizophrenia: comparative trials with amisulpride and fluphenazine.
    Saletu B; Küfferle B; Grünberger J; Földes P; Topitz A; Anderer P
    Neuropsychobiology; 1994; 29(3):125-35. PubMed ID: 7912819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparison of the effects of pipothiazine palmitate and fluphenazine decanoate. Results of a multicenter double-blind trial].
    Woggon B; Dick P; Fleischhauer HJ; Gmür M; Gruber G; Angst J; Heimann H
    Int Pharmacopsychiatry; 1977; 12(4):193-209. PubMed ID: 22515
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment.
    Itil TM; Saletu B; Hsu W; Kiremitci N; Keskiner A
    Acta Psychiatr Scand; 1971; 47(4):440-51. PubMed ID: 4947806
    [No Abstract]   [Full Text] [Related]  

  • 36. A study of the pharmacologic treatment of medication-compliant schizophrenics who relapse.
    Steingard S; Allen M; Schooler NR
    J Clin Psychiatry; 1994 Nov; 55(11):470-2. PubMed ID: 7989278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alprazolam-neuroleptic combination in schizophrenia.
    Lipinski JF; Cohen BM
    Am J Psychiatry; 1986 Nov; 143(11):1501-2. PubMed ID: 2877587
    [No Abstract]   [Full Text] [Related]  

  • 39. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lithium augmentation fails to reduce symptoms in poorly responsive schizophrenic outpatients.
    Schulz SC; Thompson PA; Jacobs M; Ninan PT; Robinson D; Weiden PJ; Yadalam K; Glick ID; Odbert CL
    J Clin Psychiatry; 1999 Jun; 60(6):366-72. PubMed ID: 10401914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.